GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
This article was originally published in The Gold Sheet
Executive Summary
As the grace period nears its close, industry officials say they expected problems getting generic drug manufacturing facilities to self-identify under the new user fee requirement; meanwhile, FDA expects to hire nearly three times the staff in the Office of Generic Drugs to meet GDUFA commitments.
You may also be interested in...
GDUFA Facility Self-Identification Pace Slow As Deadline Neared
API, finished dosage form and other facilities in the generic drug supply chain must submit information to FDA by Dec. 3. As of Nov. 18, about one-third had complied, potentially affecting user fee amounts.
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.
Generic Drugs Gain Status Boost Within CDER
More than just a bureaucratic shell game, the promotion of the Office of Generic Drugs to “super office” status signals CDER Director Janet Woodcock’s tightened focus on generic drugs.